Carlos Panizo

Carlos Panizo

Auto-generated profile, based on publicly available information

Carlos Panizo

Navarra Institute for Health Research (IdISNA), Pamplona, Spain

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2022 in Science Advances
Verified
Journal Article
Open access
SRSara Rodriguez
Sara Rodriguez
JCJon Celay
Jon Celay
IGIbai Goicoechea
Ibai Goicoechea
CJCristina Jiménez
Cristina Jiménez
CBCirino Botta
Cirino Botta
Bruno David Lourenco PaivaBruno David Lourenco Paiva
Bruno David Lourenco Paiva
Normal cell counterparts of solid and myeloid tumors accumulate mutations years before disease onset; whether this occurs in B lymphocytes before lymphoma remains uncertain. We sequenced multiple stages of the B lineage in elderly individuals and patients with lymphoplasmacytic lymphoma, a singular disease for studying lymphomagenesis because of the high prevalence of mutated MYD88 . We observed similar accumulation of random mutations in B lineages from both cohorts and unexpectedly found MYD88 L265P in normal precursor and mature B lymphocytes from patients with lymphoma. We uncovered genetic and transcriptional pathways driving malignant transformation and leveraged these to model lymphoplasmacytic lymphoma in mice, based on mutated MYD88 in B cell precursors and BCL2 overexpression. Thus, MYD88 L265P is a preneoplastic event, which challenges the current understanding of lymphomagenesis and may have implications for early detection of B cell lymphomas.

26 February 2002 in Neurology
Verified
Journal Article
Closed access
PDF file
JLJosé Manuel Martínez Lage
José Manuel Martínez Lage
CPCarlos Panizo
Carlos Panizo
JMJosé Masdeu
José Masdeu
EREduardo Rocha
Eduardo Rocha
A 26-year-old man, a professional cyclist, presented with a 2-month history of headache that had greatly increased in the previous week during a competition. There was no history of head trauma. He was referred to an institution with the diagnosis of idiopathic intracranial hypertension, which was nonresponsive to standard treatment. On admission he was cognitively normal, but reported diffuse headache with nausea, vomiting, and photophobia. Physical examination was unremarkable, except for the presence of a mild left retinal venous engorgement. A lumbar puncture disclosed an …

1 September 2004 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
CPCarlos Panizo
Carlos Panizo
MPMarta Pérez-Salazar
Marta Pérez-Salazar
MBMaurizio Bendandi
Maurizio Bendandi
MRMercedes Rodríguez-Calvillo
Mercedes Rodríguez-Calvillo
JBJosé Francisco Boán
José Francisco Boán
EREduardo Rocha
Eduardo Rocha
Given its obvious prognostic implications, the correct interpretation of the significance of any residual mediastinal mass following Hodgkin's disease (HD) treatment keeps maintaining its paramount importance. In this respect, 18F-fluorodeoxyglucose positron emission tomography (PET) is proving very effective for both active disease detection and relapse prediction. Twenty-nine consecutive HD patients, in whom computed tomography (CT) scan performed after therapy completion had documented a residual mediatinal mass of at least 2 cm, prospectively entered the study and underwent PET within 1 week from CT scan. With a median follow-up of 28 months from PET execution, no relapse was recorded among the 17 patients presenting with a negative PET. On the contrary, 9 of the 12 patients presenting with a positive PET relapsed/progressed within one year from PET execution. PET's negative and positive predictive values at 1 year were 100% and 75%, respectively. A negative PET seems to possibly exclude relapse in HD patient with a residual mediastinal mass. On the contrary, a positive PET result indicates a significantly higher risk of relapse. However, due to possible false positive results, a closer follow-up for all and a pathologic study in few selected patients is warranted.

22 March 2018 in Immunotherapy
Verified
Journal Article
Closed access
RGRicardo García‐Muñoz
Ricardo García‐Muñoz
LALorea Aguinaga
Lorea Aguinaga
JFJesus Feliu
Jesus Feliu
JAJudit Anton-Remirez
Judit Anton-Remirez
LJLorena Jorge-Del-Val
Lorena Jorge-Del-Val
CPCarlos Panizo
Carlos Panizo
Aim: Obinutuzumab induces NK cell antibody-dependent cell-mediated cytotoxicity. Objective: Investigate the effects on the human immune system after obinutuzumab monotherapy treatment in patients with chronic lymphocytic leukemia (CLL). Method: To evaluate these effects, we analyzed the distribution of CD4+ and CD8+ T cells, B cells and NK cells in the peripheral blood of eight CLL patients who were treated with obinutuzumab in monotherapy. The distribution of peripheral blood lymphocytes was examined prior to each dose of obinutuzumab and 24–72 h after the first 1000 mg complete dose (cycle 1 day 2). We also repeated measurements 3 months after the last obinutuzumab dose. In total we obtained ten samples of each patient. Analyses were performed by flow cytometry with monoclonal antibodies against CD3, CD4, CD8, CD19 and CD56+. Results: After the first 1000 mg obinutuzumab infusion (cycle 1 day 2), CD4+ T cells and CD8+ T cells were significantly decreased in peripheral blood compared with prior to therap...

1 October 2019 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
RGRicardo García‐Muñoz
Ricardo García‐Muñoz
CQCristina Quero
Cristina Quero
EPErnesto Pérez‐Persona
Ernesto Pérez‐Persona
ADAbel Domingo‐García
Abel Domingo‐García
CPCristina Pérez‐López
Cristina Pérez‐López
CPCarlos Panizo
Carlos Panizo
Summary: Rituximab is a standard treatment for non‐Hodgkin diffuse large B‐cell (DLBCL) and follicular (FL) lymphomas. A subcutaneous formulation was developed to improve the resource use of intravenous rituximab, with comparable efficacy and safety profiles except for increased administration‐related reactions (ARRs). MabRella was a phase IIIb trial to assess the safety of switching from intravenous to subcutaneous administration of rituximab during first‐line induction/maintenance for DLBCL or FL, focusing on ARRs. Efficacy, satisfaction and quality of life were also assessed. Patients received subcutaneous rituximab plus standard induction chemotherapy for DLBCL or FL for 4–7 cycles, and/or every 2 months maintenance monotherapy for FL for 6–12 cycles. The study included 140 patients: DLBCL, n = 29; FL, n = 111. Ninety‐five percent of patients experienced adverse events, reaching grade ≥3 in 38·6% and were serious in 30·0%. AARs occurred in 48·6%, mostly (84·9%) at the injection site, with only 2·1% of patients reaching grade 3. The end‐of‐induction complete/unconfirmed complete response rate was 69·6%. After a median follow‐up of 33·5 months, median disease‐/event‐/progression‐free and overall survivals were not attained. The Rituximab Administration Satisfaction Questionnaire showed improvements in overall satisfaction and the EuroQoL‐5D a good quality‐of‐life perception at induction/maintenance end. Therefore, switching to subcutaneous rituximab showed no new safety issues and maintained efficacy with improved satisfaction and quality of life.